Penn Vet | CCC Clinical Trials - Evaluation of Bendamustine as a Novel Chemotherapy Agent for Relapsed Canine Lymphoma
Contact
New Bolton Center Kennett Square, PA
Emergencies & Appointments:
610-444-5800
Directions
Ryan Hospital Philadelphia, PA
Emergencies:
215-746-8911
Appointments:
215-746-8387
Directions

Evaluation of Bendamustine as a Novel Chemotherapy Agent for Relapsed Canine Lymphoma

Apr 28, 2022

Bendamustine is a chemotherapy drug that is used to treat various types of cancer in people, including lymphoma, but it has not yet been evaluated in dogs with cancer. The purpose of this study is to evaluate different doses of bendamustine in dogs with lymphoma to evaluate its safety and effectiveness.

Dogs may be eligible for this trial after relapsing from a standard chemotherapy protocol for lymphoma. Dogs will be actively enrolled in the trial for 21 days, consisting of 5 study visits and 2 doses of bendamustine. All standard of care tests and procedures and all study-related procedures performed during study visits 1 through 5 will be paid for by the study.

For more information, please call the study coordinator at 215-573-6610 or email vcic@vet.upenn.edu.